These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 22819541)

  • 21. [Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].
    Burgos A; de Álvaro C
    Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):167-8; author reply 168-9. PubMed ID: 22244991
    [No Abstract]   [Full Text] [Related]  

  • 22. Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analyses.
    Karnon J; Orji N
    Health Policy Plan; 2016 Oct; 31(8):1133-41. PubMed ID: 27016949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National poverty reduction strategies and HIV/AIDS governance in Malawi: a preliminary study of shared health governance.
    Wachira C; Ruger JP
    Soc Sci Med; 2011 Jun; 72(12):1956-64. PubMed ID: 20675024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Not if but how? Caring for HIV-1 vaccine trial participants in South Africa.
    Tucker T; Slack C
    Lancet; 2003 Sep; 362(9388):995. PubMed ID: 14513854
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y
    J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa.
    Ngambi PG; Kalungia AC; Law MR; Kalemeera F; Truter I; Godman B; Munkombwe D
    Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):459-467. PubMed ID: 28770641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016).
    AIDS Study Group (GESIDA) of the Spanish Society of Infectious Diseases, Clinical Microbiology, the National AIDS Plan
    Enferm Infecc Microbiol Clin; 2016; 34(7):439-51. PubMed ID: 27068257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost effectiveness of antiretroviral therapy for HIV disease.
    Laurence J
    N Engl J Med; 2001 Jul; 345(1):68; author reply 68-9. PubMed ID: 11439961
    [No Abstract]   [Full Text] [Related]  

  • 30. How HIV treatment advances affect the cost-effectiveness of prevention.
    Pinkerton SD; Holtgrave DR
    Med Decis Making; 2000; 20(1):89-94. PubMed ID: 10638541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost effectiveness of antiretroviral therapy for HIV disease.
    Messori A; Trippoli S; Vaiani M
    N Engl J Med; 2001 Jul; 345(1):68; author reply 68-9. PubMed ID: 11439960
    [No Abstract]   [Full Text] [Related]  

  • 32. [Public health economic aspects of antiretroviral therapy. Can we afford to do less?].
    Stoll M; Claes C; Schulte E; Körner T; von der Schulenburg JM; Schmidt R
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():45-9. PubMed ID: 10863311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Assessment of the impact of the new health legislation on illegal immigrants in Spain: the case of human immunodeficiency virus infection].
    Pérez-Molina JA; Pulido Ortega F;
    Enferm Infecc Microbiol Clin; 2012 Oct; 30(8):472-8. PubMed ID: 22939565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The Spanish AIDS Study Group and Spanish National AIDS Plan (GESIDA/Secretaría del Plan Nacional sobre el Sida) recommendations for the treatment of tuberculosis in HIV-infected individuals (Updated January 2013)].
    Rivero A; Pulido F; Caylá J; Iribarren JA; Miró JM; Moreno S; Pérez-Camacho I; ;
    Enferm Infecc Microbiol Clin; 2013 Dec; 31(10):672-84. PubMed ID: 23541879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of visa status and Medicare eligibility on people diagnosed with HIV in Western Australia: a qualitative report.
    Herrmann S; Wardrop J; John M; Gaudieri S; Lucas M; Mallal S; Nolan D
    Sex Health; 2012 Nov; 9(5):407-13. PubMed ID: 22950904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence.
    Creese A; Floyd K; Alban A; Guinness L
    Lancet; 2002 May; 359(9318):1635-43. PubMed ID: 12020523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
    Wilkinson D; Floyd K; Gilks CF
    S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review.
    Mdege ND; Chindove S; Ali S
    Health Policy Plan; 2013 May; 28(3):223-36. PubMed ID: 22738755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
    Cook J; Dasbach E; Coplan P; Markson L; Yin D; Meibohm A; Nguyen BY; Chodakewitz J; Mellors J
    AIDS Res Hum Retroviruses; 1999 Apr; 15(6):499-508. PubMed ID: 10221527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.